 | Up a level |
Cauley, JA; Black, D; Boonen, S; Cummings, SR; Mesenbrink, P; Palermo, L; Man, Z; Hadji, P; Reid, IR; HORIZON, Pivotal Fracture Group (2011). Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial. Journal of bone and mineral research, 26(5), pp. 984-992. Hoboken, N.J.: Wiley-Blackwell 10.1002/jbmr.292
Eastell, R; Lang, T; Boonen, S; Cummings, S; Delmas, PD; Cauley, JA; Horowitz, Z; Kerzberg, E; Bianchi, G; Kendler, D; Leung, P; Man, Z; Mesenbrink, P; Eriksen, EF; Black, DM; HORIZON, Pivotal Fracture Trial. (2010). Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporosis international, 21(7), pp. 1277-85. London: Springer 10.1007/s00198-009-1077-9
Reid, DM; Devogelaer, JP; Saag, K; Roux, C; Lau, CS; Reginster, JY; Papanastasiou, P; Ferreira, A; Hartl, F; Fashola, T; Mesenbrink, P; Sambrook, PN; Perrelet, Romain; HORIZON, investigators (2009). Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet, 373(9671), pp. 1253-1263. London: Elsevier 10.1016/S0140-6736(09)60250-6
